Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications.


Entinostat is our oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. The favorable safety profile of entinostat has been demonstrated in clinical trials in more than 900 cancer patients.


SNDX-6352 is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). It has shown evidence of anti-tumor and anti-metastatic efficacy through its ability to limit the number and activity of immunosuppressive cells such as tumor associated macrophages.

Menin-MLLr inhibitors

Our Menin program includes a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia (“MLL”) protein. These compounds have potential application in the treatment of a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene (“MLL-r”).